Immunosuppressive Therapy and Risk Stratification of Patients With Myocarditis Presenting With Ventricular Arrhythmias - ScienceDirect
Frontiers | COVID-19 in Immunosuppressed Children
IKKα-deficient lung adenocarcinomas generate an immunosuppressive microenvironment by overproducing Treg-inducing cytokines | PNAS
Cancer Risk Among Immunosuppressed Populations - NCI
PDF) Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden
Cancers | Free Full-Text | Mechanisms of Immunosuppression in Colorectal Cancer | HTML
Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer - eBioMedicine
Frontiers | Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications
Immunosuppression - an overview | ScienceDirect Topics
Principles of Immunosuppression in the Management of Kidney Disease: Core Curriculum 2022 - American Journal of Kidney Diseases
Secular Trends in the Cost of Immunosuppressants after Solid Organ Transplantation in the United States | American Society of Nephrology
Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative - The Lancet Rheumatology
Tumor mutational burden and immunotherapy in gliomas: Trends in Cancer
Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer | Journal for ImmunoTherapy of Cancer
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy | Nature Reviews Clinical Oncology
JCM | Free Full-Text | Post-Transplant Cyclophosphamide and Tacrolimus—Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA ...
Targeted regulation of lymphocytic ER stress response with an overall immunosuppression to alleviate allograft rejection - ScienceDirect
Severe and multifaceted systemic immunosuppression caused by experimental cancers of the central nervous system requires release of non-steroid soluble mediators | bioRxiv
Evaluation of Changes Over Time in the Drug Burden and Medication Regimen Complexity in ESRD Patients Before and After Renal Transplantation - ScienceDirect
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets | Journal of Hematology & Oncology | Full Text
Frontiers | Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications
Managing immunosuppressive therapy in potentially cured post‐kidney transplant cancer (excluding non‐melanoma skin cancer): an overview of the available evidence and guidance for shared decision‐making - Hellemans - 2021 - Transplant International -
